PL3134438T3 - Przeciwciało IGF-1R i jego zastosowanie jako nośnika kierującego do leczenia nowotworów - Google Patents

Przeciwciało IGF-1R i jego zastosowanie jako nośnika kierującego do leczenia nowotworów

Info

Publication number
PL3134438T3
PL3134438T3 PL15727884T PL15727884T PL3134438T3 PL 3134438 T3 PL3134438 T3 PL 3134438T3 PL 15727884 T PL15727884 T PL 15727884T PL 15727884 T PL15727884 T PL 15727884T PL 3134438 T3 PL3134438 T3 PL 3134438T3
Authority
PL
Poland
Prior art keywords
igf
antibody
cancer
treatment
addressing vehicle
Prior art date
Application number
PL15727884T
Other languages
English (en)
Inventor
Liliane Goetsch
Matthieu BROUSSAS
Charlotte Beau-Larvor
Thierry Champion
Alain Robert
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of PL3134438T3 publication Critical patent/PL3134438T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL15727884T 2014-04-25 2015-04-27 Przeciwciało IGF-1R i jego zastosowanie jako nośnika kierującego do leczenia nowotworów PL3134438T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984160P 2014-04-25 2014-04-25
EP15727884.7A EP3134438B1 (en) 2014-04-25 2015-04-27 Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
PCT/EP2015/059050 WO2015162292A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody and its use as addressing vehicle for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL3134438T3 true PL3134438T3 (pl) 2021-04-06

Family

ID=53373391

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15727884T PL3134438T3 (pl) 2014-04-25 2015-04-27 Przeciwciało IGF-1R i jego zastosowanie jako nośnika kierującego do leczenia nowotworów

Country Status (29)

Country Link
US (2) US10202458B2 (pl)
EP (2) EP3134438B1 (pl)
JP (2) JP6835591B2 (pl)
KR (3) KR102177436B1 (pl)
CN (2) CN112851808B (pl)
AU (1) AU2015250760C1 (pl)
BR (1) BR112016024575B1 (pl)
CA (1) CA2946795C (pl)
CY (1) CY1123743T1 (pl)
DK (1) DK3134438T3 (pl)
ES (1) ES2841249T3 (pl)
HR (1) HRP20202047T1 (pl)
HU (1) HUE052223T2 (pl)
IL (2) IL248357B (pl)
LT (1) LT3134438T (pl)
MA (2) MA53069B1 (pl)
MX (2) MX380358B (pl)
MY (1) MY182444A (pl)
NZ (1) NZ725423A (pl)
PL (1) PL3134438T3 (pl)
PT (1) PT3134438T (pl)
RS (1) RS61379B1 (pl)
RU (1) RU2698977C2 (pl)
SA (1) SA516380131B1 (pl)
SI (1) SI3134438T1 (pl)
TN (1) TN2016000445A1 (pl)
UA (1) UA122390C2 (pl)
WO (1) WO2015162292A1 (pl)
ZA (1) ZA201607095B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190888T8 (hr) * 2014-04-25 2019-10-04 Pierre Fabre Médicament Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
KR20180105634A (ko) * 2015-10-26 2018-09-28 피에르 파브르 메디카먼트 Igf-1r을 발현하는 암의 치료를 위한 조성물
EP3565841A1 (en) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
EP3710478A1 (en) 2017-11-13 2020-09-23 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
EP3856258B1 (en) 2018-09-27 2024-07-31 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
WO2020079229A1 (en) * 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20220306736A1 (en) 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2661000B1 (fr) 1990-04-12 1992-08-07 Aerospatiale Machine d'essais d'eprouvettes en cisaillement.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561427A (en) 1994-12-30 1996-10-01 Psc Inc. Analog to digital converter with continuous conversion cycles and large input signal range
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US8476409B2 (en) * 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Also Published As

Publication number Publication date
KR20200128210A (ko) 2020-11-11
LT3134438T (lt) 2021-01-11
JP2017513898A (ja) 2017-06-01
EP3134438B1 (en) 2020-09-30
CN112851808B (zh) 2024-12-06
KR102357032B1 (ko) 2022-02-08
US20170267766A1 (en) 2017-09-21
RU2016145277A3 (pl) 2018-12-13
JP2021073279A (ja) 2021-05-13
IL274226A (en) 2020-06-30
BR112016024575A2 (pt) 2017-10-10
HUE052223T2 (hu) 2021-04-28
DK3134438T3 (da) 2020-12-07
TN2016000445A1 (en) 2018-04-04
MX2021002144A (es) 2021-03-09
ZA201607095B (en) 2020-07-29
IL248357B (en) 2020-05-31
MA53069A1 (fr) 2021-10-29
US10202458B2 (en) 2019-02-12
EP3783033A1 (en) 2021-02-24
MY182444A (en) 2021-01-25
ES2841249T3 (es) 2021-07-07
MA39378B2 (fr) 2021-02-26
MA39378A1 (fr) 2018-05-31
KR20220018620A (ko) 2022-02-15
AU2015250760A1 (en) 2016-11-03
CY1123743T1 (el) 2022-03-24
CN106459204B (zh) 2021-02-02
MX2016014000A (es) 2017-05-30
US20190330353A1 (en) 2019-10-31
EP3134438A1 (en) 2017-03-01
PT3134438T (pt) 2020-12-31
JP6835591B2 (ja) 2021-02-24
SA516380131B1 (ar) 2019-12-04
JP7191134B2 (ja) 2022-12-16
CA2946795A1 (en) 2015-10-29
WO2015162292A1 (en) 2015-10-29
SI3134438T1 (sl) 2021-04-30
RU2016145277A (ru) 2018-05-28
MA53069B1 (fr) 2022-04-29
CN112851808A (zh) 2021-05-28
AU2015250760B2 (en) 2020-10-22
UA122390C2 (uk) 2020-11-10
US11365259B2 (en) 2022-06-21
HRP20202047T1 (hr) 2021-02-19
CN106459204A (zh) 2017-02-22
KR102177436B1 (ko) 2020-11-12
IL248357A0 (en) 2016-11-30
BR112016024575B1 (pt) 2024-02-27
RU2698977C2 (ru) 2019-09-02
RS61379B1 (sr) 2021-02-26
KR20160145110A (ko) 2016-12-19
CA2946795C (en) 2021-03-30
AU2015250760C1 (en) 2023-11-16
MX380358B (es) 2025-03-12
NZ725423A (en) 2023-07-28

Similar Documents

Publication Publication Date Title
IL274226A (en) IGF-1R antibody and its use as a preventive measure for cancer treatment
IL248455A0 (en) igf-1r antibody-drug conjugate and its use for cancer treatment
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
ZA201802831B (en) Composition for the treatment of igf-1r expressing cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
EP3153357A4 (en) Vehicle body component
SI3122358T1 (sl) Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
EP3178729A4 (en) Vehicle body structure
EP3148526A4 (en) Use of eribulin in the treatment of cancer
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3157562A4 (en) Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
EP2991650A4 (en) Methods for the treatment of cancer
IL255273A0 (en) igf-1r antibody and its use for cancer diagnosis
ZA201707247B (en) Igf-1r antibody and its use for the diagnosis of cancer
EP3102940A4 (en) Anti-metalloprotease antibody for diagnosis and treatment of cancers
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer
EP3125903A4 (en) Method for use of homopiperazinium compounds in the treatment of cancer